The efficacy of group hypnosis and relaxation in smoking cessation

Smoking cessation through group hypnosis: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN72839675

Enrollment

172

Registered

2011-08-26

Start date

2011-04-20

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Public health, smoking, hypnosis, smoking cessation Mental and Behavioural Disorders Mental and behavioural disorders due to use of tobacco

Interventions

Two groups to be compared: 1. Participants receive 40 minutes of motivational training followed by 40 minutes of hypnosis in a group session (8 to 15 participants) 2. Participants receive 40 minutes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65 years 2. Smoking five or more cigarettes per day 3. Not taking any medication or following another program for smoking cessation 4. Willing to stop smoking 5. Not suffering from alcohol dependence or psychotic disorders 6. No intake of stimulating medication such as methylphenidate (Ritalin) or venlafaxine (Effexor®)

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Number of participants smoking 2 weeks after each intervention (smoking defined as 5 or more cigarettes per day) (inter-subject design) 2. Number of participants smoking 6 months after each intervention (inter-subject design) 3. Changes in the number of daily cigarettes smoked from baseline to 2 weeks after the intervention (intra-subject design) 4. Changes in the number of daily cigarettes smoked from baseline to 6 months after the intervention (intra-subject design) 5. Changes in salivary cotinine levels from baseline to 6 months after the intervention (intra-subject design)	—

Measure

Time frame

1. Number of participants smoking 2 weeks after each intervention (smoking defined as 5 or more cigarettes per day) (inter-subject design) 2. Number of participants smoking 6 months after each intervention (inter-subject design) 3. Changes in the number of daily cigarettes smoked from baseline to 2 weeks after the intervention (intra-subject design) 4. Changes in the number of daily cigarettes smoked from baseline to 6 months after the intervention (intra-subject design) 5. Changes in salivary cotinine levels from baseline to 6 months after the intervention (intra-subject design)

—

Secondary

Measure	Time frame
1. Depression (BDI-V, Schmitt et al. 2003; 2006) at baseline, 2 weeks and 6 months after the intervention 2. Anxiety (BAI, Beck et al. 1988, German version by Margraf & Ehlers) at baseline, 2 weeks and 6 months after the intervention 3. Expected self-efficacy in situations of high smoking temptation (Tönjes et al., 2007) at baseline and 2 weeks after the intervention 4. Adverse events (headache, insomnia, gastrointestinal problems etc.) 2 weeks and 6 months after the intervention	—

Measure

Time frame

1. Depression (BDI-V, Schmitt et al. 2003; 2006) at baseline, 2 weeks and 6 months after the intervention 2. Anxiety (BAI, Beck et al. 1988, German version by Margraf & Ehlers) at baseline, 2 weeks and 6 months after the intervention 3. Expected self-efficacy in situations of high smoking temptation (Tönjes et al., 2007) at baseline and 2 weeks after the intervention 4. Adverse events (headache, insomnia, gastrointestinal problems etc.) 2 weeks and 6 months after the intervention

—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 26, 2026